FY2027 EPS Estimates for Nanobiotix Boosted by HC Wainwright

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) – Research analysts at HC Wainwright boosted their FY2027 earnings per share estimates for shares of Nanobiotix in a report released on Thursday, October 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.23) per share for the year, up from their previous forecast of ($0.26). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Nanobiotix’s FY2028 earnings at $0.75 EPS and FY2029 earnings at $1.50 EPS.

Several other research analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Saturday, September 27th. Leerink Partners set a $14.00 target price on Nanobiotix in a report on Thursday, September 18th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.00.

Nanobiotix Stock Performance

Shares of Nanobiotix stock opened at $20.51 on Monday. The stock’s 50 day simple moving average is $10.28 and its 200-day simple moving average is $6.28. Nanobiotix has a 1-year low of $2.76 and a 1-year high of $21.12.

Institutional Trading of Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Millennium Management LLC acquired a new position in shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 13,452 shares of the company’s stock, valued at approximately $39,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.